Neovasculgen

Neovasculgen is a gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF).[1][2] Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.[3][4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

Neovasculgen
Gene therapy
Target genedelivers new VEGF
Clinical data
Trade namesNeovasculgen
Other namesPl-VEGF165
Routes of
administration		Intraneural injection
ATC code
Identifiers
ChemSpider
  • none

References
  1. AdisInsight Vascular endothelial growth factor gene therapy - HSCI Page accessed 5 June 2016
  2. "Gene Therapy for PAD Approved". 6 December 2011. Retrieved 5 August 2015.
  3. Eurolab. Neovasculogen listing in Eurolab Page accessed 4 August 2015
  4. Deev, R.; Bozo, I.; Mzhavanadze, N.; Voronov, D.; Gavrilenko, A.; Chervyakov, Yu.; Staroverov, I.; Kalinin, R.; Shvalb, P.; Isaev, A. (13 March 2015). "pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia". Journal of Cardiovascular Pharmacology and Therapeutics. 20 (5): 473–82. doi:10.1177/1074248415574336. PMID 25770117.

See also


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.